Results 101 to 110 of about 55,182 (234)

Beyond Efficacy: Ensuring Safety in Peptide Therapeutics through Immunogenicity Assessment

Journal of Peptide Science, Volume 31, Issue 6, June 2025.
Peptides are increasingly used in diagnosis and treatment due to their selectivity and low side effects. Over 11% of FDA‐approved drugs from 2016 to 2024 were synthetic peptides. However, immunogenicity—an adverse immune response—can limit their safety and efficacy.
Koulla Achilleos, Christos Petrou, Vicky Nicolaidou, Yiannis Sarigiannis   +3 more
wiley   +1 more source

Thyrotoxicosis, hyperparathyroidism, and hyperuricaemia. [PDF]

, 1966
J. K. Nelson, David R. Hadden
openalex   +1 more source

Hyperparathyroidism [PDF]

Wiener Medizinische Wochenschrift, 2013
openaire   +3 more sources

Ferric Carboxymaltose (FCM)–Associated Hypophosphatemia (HPP): A Systematic Review

American Journal of Hematology, Volume 100, Issue 5, Page 840-846, May 2025.
ABSTRACT Background Since 2015, ferric carboxymaltose (FCM), an intravenous (IV) iron formulation used for treating iron deficiency anemia (IDA), has been associated with an increasing number of reported hypophosphatemia (HPP) cases. Information on HPP clinical manifestations and incidence has not been reviewed.
Joseph Magagnoli, Kevin Knopf, William J. Hrushesky, Kenneth R. Carson, Charles L. Bennett   +4 more
wiley   +1 more source

Acromegaly and Hyperparathyroidism [PDF]

, 1967
P Hübner
openalex   +1 more source

Cytopathology of follicular and oncocytic follicular thyroid neoplasms: A Bethesda System perspective

Cancer Cytopathology, Volume 133, Issue 5, May 2025.
Abstract The third edition of The Bethesda System for Reporting Thyroid Cytopathology includes category IV, follicular neoplasm (FN), which is used to classify fine‐needle aspirates of thyroid nodules that may correspond to invasive follicular‐derived neoplasia other than papillary thyroid carcinoma.
André Lametti, Fadi Brimo, Yonca Kanber, Derin Caglar, Manon Auger   +4 more
wiley   +1 more source

Primary Hyperparathyroidism, Acute Urinary Infection and Pancreatitis [PDF]

, 1963
S. Jawaheer
openalex   +1 more source

Microdose Cocktail Study Reveals the Activity and Key Influencing Factors of OATP1B, P‐Gp, BCRP, and CYP3A in End‐Stage Renal Disease Patients

Clinical Pharmacology &Therapeutics, Volume 117, Issue 5, Page 1303-1312, May 2025.
OATP1B, P‐gp, BCRP, and CYP3A are the most contributing drug‐metabolizing enzymes or transporters (DMETs) for commonly prescribed medication. Their activities may change in end‐stage renal disease (ESRD) patients with large inter‐individual variabilities (IIVs), leading to altered substrate drug exposure and ultimately elevated safety risk.
Weijie Kong, Yuejuan Pan, Yujie Wu, Yiyi Hu, Zhenbin Jiang, Xinkui Tian, Shuhong Bi, Song Wang, Feifei Feng, Yuyan Jin, Jiayu Li, Haiyan Li, Yue Wang, Hao Liang, Wen Tang, Dongyang Liu   +15 more
wiley   +1 more source

Oral Phosphates for Hyperparathyroidism [PDF]

, 1963
J R Gill, D. E. Hellman, Frederic C. Bartter   +2 more
openalex   +1 more source

Extreme hypercalcemia secondary to parathyroid adenoma obscured by excessive coffee consumption and premature ventricular complexes

Journal of General and Family Medicine, Volume 26, Issue 3, Page 263-266, May 2025.
Diagnostic biases are potentially life‐threatening. We present a case of extreme hypercalcemia falsely diagnosed as premature ventricular complexes attributed to heavy coffee consumption, while symptoms and electrocardiographic findings of hypercalcemia were disregarded. Abstract Severe hypercalcemia has an arrhythmogenic effect. We present a case of a
Yuval Avidan, Sameer Kassem
wiley   +1 more source